Biased research, aggressive sales, harmful drugs
The Health Policy Exchange
MAY 20, 2013
Food and Drug Administration to market a new drug is a critical waypoint along the path to profits for pharmaceutical manufacturers. Very quickly, the market included nearly all dialysis patients, not just the roughly 16 percent who required blood transfusions. Approval from the U.S. The size of average doses would more than triple.
130 
Let's personalize your content